DCN Dx and QIAGEN Lake Constance are pleased to announce the second Rapid Testing Innovation Award. The award, which includes a cash prize of $10,000, will be presented at the 2019 Advanced Lateral Flow Course in October. The award recognizes the best innovation in rapid point-of-care assays or the most creative application for rapid assays during the past year.
DCN Dx, Inc., a leading developer of rapid point-of-care diagnostic tests, announced today that John L. Tonkinson, Ph.D. has joined the company in the newly created role of Chief Business Development Officer. In this role, Dr. Tonkinson will be responsible for defining and implementing a strategic growth plan to enable the company to maintain its position as the recognized leader in the development of point-of-care diagnostic tests and the definitive training resource for developing lateral flow immunoassays.
Over the last 15 years, Dr. Tonkinson has developed and led commercial efforts at several biotechnology companies with a focus on building teams and establishing business models to bring technologies and manufacturing capabilities to broader markets. Earlier in his career, he ran an R&D team at S&S Bioscience that was responsible for developing materials and products for lateral flow assays, solid phase blood collection and separation, and micro-spot ELISA assays on thin films.